Mirum's Hepatitis Delta Drug Meets Trial Goal With 59% Response Versus 0%

A second late-stage success supports Mirum's planned FDA application in the first half of 2027.

Share
Mirum's Hepatitis Delta Drug Meets Trial Goal With 59% Response Versus 0%

Mirum Pharmaceuticals, which develops medicines for rare diseases, said Tuesday that its experimental hepatitis delta drug brelovitug achieved a 59% combined response with weekly dosing, versus 0% with delayed treatment, meeting the main goal of a late-stage trial. The results, announced in an SEC filing, give Mirum a second successful late-stage study for its planned U.S. approval application.

Viral Response Outpaces Combined Response

The main measure required both a response in virus levels and normalization of ALT, a liver enzyme. At 24 weeks, 44% of patients receiving brelovitug every four weeks met that combined measure; viral response alone reached 95% with weekly treatment and 96% with treatment every four weeks.

The global trial enrolled 113 previously untreated patients. They were randomly assigned to self-administered weekly injections of 300 milligrams, 900-milligram injections every four weeks, or delayed treatment beginning at week 12. Cirrhosis affected 53% of participants.

Mirum reported no new safety signals. Flu-like illness affected 17.2% of weekly-dose patients and 18.5% of those treated every four weeks, with most cases occurring after the first dose. Injection-site reactions occurred in 1.7% and 7.4%, respectively.

Longer Treatment Adds Cirrhosis Evidence

The earlier late-stage trial recorded combined responses of 56% and 45% at 24 weeks, with viral responses of 86% and 85%. Neither late-stage study's delayed-treatment group achieved the main combined measure.

Mid-stage results extended the treatment window: both dosing groups achieved a 55% combined response at 48 weeks, while viral response reached 95% in each group.

At 108 weeks, all 15 patients with cirrhosis in a separate mid-stage study achieved both viral response and ALT normalization. Those patients received 900 milligrams every four weeks in the extension, with patients on other initial regimens switching at week 48. Mirum also pointed to improvements in liver stiffness in longer-term results presented at the American Association for the Study of Liver Diseases' The Liver Meeting.

Brelovitug Joins A Rare-Disease Portfolio

Mirum gained brelovitug through its purchase of Bluejay Therapeutics on January 23, 2026. The experimental antibody binds to hepatitis B surface antigen and is being studied for chronic hepatitis delta.

Mirum's approved medicines are Livmarli, an oral treatment for itching associated with Alagille syndrome and progressive familial intrahepatic cholestasis; Cholbam, for bile acid synthesis disorders and certain peroxisomal disorders; and Ctexli, for adults with cerebrotendinous xanthomatosis.

The company sells Livmarli directly in the United States, Canada and certain European countries. Cholbam and Ctexli reach U.S. patients through one specialty pharmacy, while other rare-disease companies license or distribute Mirum medicines in additional countries. Its development pipeline also includes volixibat for adult liver diseases and MRM-3379 for fragile X syndrome.

Mirum plans to submit its FDA approval application in the first half of 2027. A potential U.S. launch would follow in the fourth quarter of 2027, if approved.

Sources

More on Mirum Pharmaceuticals

All Mirum Pharmaceuticals (MIRM) coverage →